Glenmark Pharma’s arm receives USFDA’s approval for Pimecrolimus Cream

30 Aug 2019

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Pimecrolimus Cream, 1%, a generic version of Elidel Cream, 1%, of Bausch Health US, LLC.

According to IQVIA sales data for the 12 month period ending July 2019, the Elidel Cream, 1% market achieved annual sales of approximately $198.8 million.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Related Glenmark Pharmaceuticals Ltd. Links:

Glenmark Pharma Share Price

301.20 18.90 (6.70%) Nov 15, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 414.90
Lupin 742.25
Dr. Reddys Lab 2730.35
Piramal Enterprises 1767.20
Cadila Healthcare 234.35
View more..
Sensex vs Glenmark Pharma
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback

8055769463

8055769463